|  |
| |
Description | There are two major isoforms of STAT2. The long form is known as isoform 1 and is a 851 amino acid protein (113KDa on gels). Isoform 2 lacks an internal four amino acid segment compared to isoform 1. The STAT2 gene product contains 6 domains: an N-terminal domain (NTD), a coiled-coil domain (CC), a DNA-binding domain (DBD), a linker domain (LD), a Src homology-2 domain (SH2), and a transactivation domain (TAD) (figure 1). NTD is required for tyrosine phosphorylation of STAT2 in response to type I IFNs, binding of STAT2 to IFN receptors and cooperative binding of STAT1:STAT2 heterodimers or ISGF3 to promoters that contain tandem GAS or ISRE, respectively. CC mediates protein interactions and is the domain IRF9 binds. DBD does not bind DNA as a part of ISGF3. DBD contains a bipartite nuclear localization signal (NLS) when ISGF3 forms. No function for LD is known. SH2 serves 2 main functions: binding to a phosphorylated IFN receptor, thereby making STAT2 available for Tyk2-mediated tyrosine phosphorylation; and binding to tyrosine phosphorylated STAT1 to form an active heterodimer. The TAD is essential for recruitment of transcription regulators. TAD also contains the nuclear export signal (NES). Nucleocytoplasmic shuttling of STAT2 is attributed to the constitutive binding of STAT2 to the NLS-containing IRF9 to transport STAT2 into the nucleus, while the STAT2 NES exports STAT2 back to the cytosol (Steen and Gamero, 2012). Interferons (IFNs) activate the Janus kinase (JAK)/STAT pathway by binding to their corresponding receptor complex. Jak1 and TYK2 are pre-associated with type I and type III IFN receptors, and phosphorylate specific tyrosine residues within the receptor chain, which serve as docking sites for the recruitment of STATs. JAKs phosphorylate a conserved tyrosine residue situated in the C-terminal region of STAT2 (Y690) and STAT1 , thus allowing STAT1 and STAT2 to interact via reciprocal SH2-phosphotyrosyl interactions. Formation of the interferon-stimulated gene factor 3 (ISGF3) complex takes place when activated STAT1:STAT2 heterodimers are released from receptor chains to bind the DNA-binding adaptor protein, IRF9 (p48/ISGF3G). ISGF3 translocates to the nucleus and binds the DNA containing an IFN-stimulated response element (ISRE) by STAT1 and IRF9 to activate gene transcription of IFN-stimulated genes (ISGs). In addition, STAT2 can form heterodimers individually with either STAT1 or IRF9. Each of these complexes will bind IRSE or IFN-gamma activation sequences (GAS) to activate gene transcription of ISGs. Serine 287 phosphorylation can negatively regulate the biological activities of type I IFNs (Steen et al., 2013). IFNs are the only cytokines known to date that can activate STAT2. |
Expression | STAT2 is ubiquitously expressed in most cell types. |
Localisation | STAT2 predominantly resides in the cytoplasm. Nucleocytoplasmic shuttling occurs in the absence of IFN stimulation, but translocates to the nucleus upon tyrosine phosphorylation when stimulated by IFNs (Reich, 2013). |
Function | Transcription factor. STAT2 mediates the transcription of numerous IFN-induced genes involved in linking adaptive and innate immunity and exerting antiviral, antiproliferative, apoptotic, and antitumor effects. |
Homology | Shares homology with the other 6 mammalian STAT genes: STAT1, STAT3, STAT4, STAT5A, STAT5B, STAT6. Human STAT2 is relatively well conserved with macaque and chimpanzee. Human and murine STAT2 are highly homologous (76% identity over the first 712 amino acids). |
Suppression of type I interferon signaling proteins is an early event in squamous skin carcinogenesis |
Clifford JL, Walch E, Yang X, Xu X, Alberts DS, Clayman GL, El-Naggar AK, Lotan R, Lippman SM |
Clin Cancer Res 2002 Jul;8(7):2067-72 |
PMID 12114405 |
|
Expression of STATs and their inhibitors SOCS and PIAS in brain tumors |
Ehrmann J, Strakova N, Vrzalikova K, Hezova R, Kolar Z |
In vitro and in vivo study Neoplasma |
PMID 18999875 |
|
STAT2 contributes to promotion of colorectal and skin carcinogenesis |
Gamero AM, Young MR, Mentor-Marcel R, Bobe G, Scarzello AJ, Wise J, Colburn NH |
Cancer Prev Res (Phila) 2010 Apr;3(4):495-504 |
PMID 20233899 |
|
STAT2 deficiency and susceptibility to viral illness in humans |
Hambleton S, Goodbourn S, Young DF, Dickinson P, Mohamad SM, Valappil M, McGovern N, Cant AJ, Hackett SJ, Ghazal P, Morgan NV, Randall RE |
Proc Natl Acad Sci U S A 2013 Feb 19;110(8):3053-8 |
PMID 23391734 |
|
The Tumor Suppressive Effects of HPP1 Are Mediated Through JAK-STAT-Interferon Signaling Pathways |
Hernandez JM, Elahi A, Clark W, Humphries LA, Wang J, Achille A, Seto E, Shibata D |
DNA Cell Biol 2015 May 19 |
PMID 26061044 |
|
Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines |
Krishnamurthy S, Takimoto T, Scroggs RA, Portner A |
J Virol 2006 Jun;80(11):5145-55 |
PMID 16698995 |
|
cDNA-array profiling of melanomas and paired melanocyte cultures |
Mischiati C, Natali PG, Sereni A, Sibilio L, Giorda E, Cappellacci S, Nicotra MR, Mariani G, Di Filippo F, Catricalà C, Gambari R, Grammatico P, Giacomini P |
J Cell Physiol 2006 Jun;207(3):697-705 |
PMID 16523488 |
|
Selective activation of members of the signal transducers and activators of transcription family in prostate carcinoma |
Ni Z, Lou W, Lee SO, Dhir R, DeMiguel F, Grandis JR, Gao AC |
J Urol 2002 Apr;167(4):1859-62 |
PMID 11912448 |
|
STATs get their move on |
Reich NC |
JAKSTAT 2013 Oct 1;2(4):e27080 |
PMID 24470978 |
|
Identification of STAT2 serine 287 as a novel regulatory phosphorylation site in type I interferon-induced cellular responses |
Steen HC, Nogusa S, Thapa RJ, Basagoudanavar SH, Gill AL, Merali S, Barrero CA, Balachandran S, Gamero AM |
J Biol Chem 2013 Jan 4;288(1):747-58 |
PMID 23139419 |
|
Identification of alternative splicing form of Stat2 |
Sugiyama T, Nishio Y, Kishimoto T, Akira S |
FEBS Lett 1996 Mar 4;381(3):191-4 |
PMID 8601453 |
|
Host STAT2/type I interferon axis controls tumor growth |
Yue C, Xu J, Tan Estioko MD, Kotredes KP, Lopez-Otalora Y, Hilliard BA, Baker DP, Gallucci S, Gamero AM |
Int J Cancer 2015 Jan 1;136(1):117-26 |
PMID 24895110 |
|